Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.34
+0.35 (3.18%)
Mar 25, 2026, 4:00 PM EDT - Market closed

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Developing Novel Therapeutics
244.06M3.55M151.00K
20.10M
10.00M
Developing Novel Therapeutics Growth
6774.96%2250.99%-
-
0%
Total
244.06M3.55M151.00K
20.10M
10.00M
Total Growth
6774.96%2250.99%-
-
0%
Source: S&P Global Market Intelligence.